je.st
news
Tag: drug
Patheon To Host A Seminar On "Getting Your Drug Through Phase I Early Development Effectively"
2013-02-11 09:54:33| drugdiscoveryonline Home Page
Patheon will host a complimentary Seminar on “Getting Your Drug through Phase I Early Development Effectively” at the Milton Park, UK Facilit. The seminar will be held on Tuesday, February 19th at 11:30 – 6 p.m. Central European Time at Patheon’s Milton Park facility in Oxfordshire, UK.
Tags: development
early
drug
host
Dotmatics Vortex Selected To Boost Drug Discovery Efforts At The University Of Leeds
2013-02-11 07:20:00| drugdiscoveryonline News Articles
Dotmatics Limited, a leading provider of informatics services to academia as well as the pharmaceutical, biotech and chemical industries, recently announced that the University of Leeds has deployed Vortex, its premium scientific intelligence tool, to analyse complex data and help with its life science research efforts
Tags: university
selected
efforts
drug
Dotmatics Vortex Selected To Boost Drug Discovery Efforts At The University Of Leeds
2013-02-11 07:20:00| drugdiscoveryonline Home Page
Dotmatics Limited, a leading provider of informatics services to academia as well as the pharmaceutical, biotech and chemical industries, recently announced that the University of Leeds has deployed Vortex, its premium scientific intelligence tool, to analyse complex data and help with its life science research efforts
Tags: university
selected
efforts
drug
Shire to pay Impax $48 million to settle suit over ADHD drug
2013-02-10 12:23:51| Biotech - Topix.net
Shire P.L.C. will pay $48 million to Impax Laboratories Inc. to settle litigation between the two drugmakers over delivery of generic Adderall XR, which is supposed to be used to treat attention deficit hyperactivity disorder.
U.S. Food and Drug Administration Approves POMALYST (pomalidomide)...
2013-02-09 07:14:10| Biotech - Topix.net
Celgene Corporation today announced the U.S. Food and Drug Administration has approved POMALYSTA brand therapy for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Tags: food
administration
drug
drug administration
Sites : [270] [271] [272] [273] [274] [275] [276] [277] [278] [279] [280] [281] [282] [283] [284] [285] [286] [287] [288] [289] next »